Bereiche

Link

Kontakt

---

Zitation

Art

Veröffentlichungsdatum

Ausgabe

ISBN Nummer

Seiten

Verlag

Kurzbeschreibung/Zielsetzung

xi
Preface (Second Edition)
We would like to thank the readers of this book’s fi rst edition. A very satisfying number of
people were interested in the fi rst edition. We received a lot of very positive feedback from
many rheumatologists and other colleagues working in the fi eld.
The fast recent development of clinical rheumatology has made it necessary to prepare
a second edition. For this new edition which additionally covers the period between
January 2010 and 2012, we have selected and added 177 studies to the ones from the fi rst
edition. Most of these studies were published in the period between January 2010 and
December 2011, but also older ones which appeared to be valuable additions have been
included. Due to the added content and the consequently growing size, Clinical Trials in
Rheumatology is now published in two volumes: the fi rst on arthritic diseases and the second
on connective tissue diseases/vasculitis.
We have improved the clarity of the presentation by replacing the former simple lists
presenting the clinical results and side effects of each trial by tables. We have further tried
to eliminate as many of the mistakes of the fi rst edition as possible.
In the chapter on rheumatoid arthritis, ‘… patients with rheumatoid arthritis’ in the
‘Patients’ section implies a diagnosis based on the 1987 ACR criteria.
The chapters on polymyalgia rheumatica and giant cell arteritis have now been merged.
The respective disease entity and substance are indicated in the page header.
The chapter name “ANCA-associated vasculitis, Churg Straus Syndrome, and othervasculitic entitities” in the fi rst edition has been renamed since it did not fi t the generally
accepted Chapel Hill classi fi cation of vasculitis. The part ‘… combination trials of Churg Strauss Syndrome and Panarteriitis nodosa’ in the new title was necessary because of
Guillevain’s studies which combined patients with these two disorders on the basis of the older Fauci classi fi cation. In addition, page headers naming the respective disease and
substance have been added.